Roche’s Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – …
Pharma Newswire™ is part of GroupWeb Media Network. © 2025 GroupWeb Media LLC
Roche’s Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – …
Listen to the article 6 min This audio is auto-generated. Please let us know if you have feedback. Diagnostics companies …
The challenges facing biotechs amid the ongoing financial fallout have resulted in the winding down of one US biotech, Vor …
Listen to the article 7 min This audio is auto-generated. Please let us know if you have feedback. The days …
A Maryland man who has lost his vision due to non-arteritic anterior ischaemic optic neuropathy (NAION) is suing Novo Nordisk, …
Listen to the article 7 min This audio is auto-generated. Please let us know if you have feedback. A lot …
Robert F Kennedy Jr’s controversial views on vaccines were on display this week during an interview with CBS News in …
Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dr. Mehmet …
A formulation of MSD’s cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared …
Listen to the article 7 min This audio is auto-generated. Please let us know if you have feedback. The stock …
Pharma Newswire™ aggregates, publishes and distributes news in the Pharmaceutical Industry. In association with EmailWire, Pharma Newswire™ provides press release distribution services in the pharmaceutical sector. Press releases are disseminated to journalists, experts, investors, trade publications and other related media outlets. To send a press release, contact us through the following messaging apps:
Pharma Newswire™ is part of GroupWeb Media Network. © 2025 GroupWeb Media LLC